Table 4.
Univariate and multivariate analyses of disease‐free survival in stages I–III breast cancer patients (n = 141)
| Variable | Univariate | Mutivariate | ||
|---|---|---|---|---|
| P‐value | Relative risk (95% CI) | P‐value | Relative risk (95% CI) | |
| miR‐1 status (positive/negative) | <0.0001 * | 6.90 (3.25–14.64) | 0.017 | 3.50 (1.26–9.78) |
| Ki‐67 LI ** (1–98%) | <0.0001 * | 1.05 (1.01–1.09) | 0.12 | 1.03 (0.99–1.06) |
| pT (pT1/pT2‐4) | 0.0001 * | 0.19 (0.08–0.44) | 0.0098 | 0.22 (0.07–0.70) |
| Adjvant endocrine therapy (received/not received) | 0.0009 * | 0.27 (0.12–0.59) | 0.43 | 0.63 (0.20–1.98) |
| PR status (positive/negative) | 0.0065 * | 0.35 (0.17–0.75) | 0.64 | 0.34 (0.11–1.07) |
| Lymph node metastasis (positive/negative) | 0.0066 * | 2.92 (1.35–6.33) | 0.73 | 0.83 (0.28–2.46) |
| ER status (positive/negative) | 0.079 * | 0.50 (0.23–1.08) | 0.37 | 1.84 (0.49–6.86) |
| Histological grade (1,2/3) | 0.091 * | 0.52 (0.24–1.11) | 0.26 | 2.04 (0.59–7.06) |
| Ajuvant chemotherapy (received/not received) | 0.15 | 1.84 (0.80–4.02) | ||
| HER2 status (positive/negative) | 0.33 | 1.81 (0.55–6.00) | ||
Statistical analysis was evaluated by a proportional hazard model (Cox). P < 0.05 and 0.05 ≤ P < 0.10 were considered significant and borderline significant, and are listed in bold and italic, respectively. *Significant (P < 0.05) and borderline‐significant (0.05 ≤ P < 0.10) values were examined in the multivariate analyses in this study. **Data were evaluated as continuous variables, and all other data were evaluated as dichotomized variables. 95% CI, 95% confidence interval.